Intellia Therapeutics Schedules Q4 and Full-Year 2025 Earnings Call
Event summary
- Intellia Therapeutics will host a conference call on February 26, 2026, at 8 a.m. ET to discuss Q4 and full-year 2025 financial results and business updates.
- The call will be available via webcast and teleconference, with a replay accessible for 90 days on the company's website.
- Intellia Therapeutics is a clinical-stage gene editing company focused on CRISPR-based therapies.
The big picture
Intellia Therapeutics' earnings call comes at a time when the biotech industry is increasingly focused on the potential of gene editing technologies. The company's progress in developing CRISPR-based therapies will be closely watched, particularly in light of the competitive landscape and the need for novel treatments in areas with significant unmet medical needs. The call will provide insights into Intellia's financial health and strategic direction as it aims to set the standard for a new class of medicine.
What we're watching
- Financial Performance
- How Intellia's Q4 and full-year 2025 financial results will reflect its progress in developing CRISPR-based therapies.
- Pipeline Updates
- Whether the company will provide updates on its clinical-stage programs and potential regulatory milestones.
- Strategic Shifts
- The pace at which Intellia is expanding its CRISPR-based platform with novel editing and delivery technologies.
Related topics